Frank Ga Jansman

Summary

Affiliation: Isala Klinieken
Country: The Netherlands

Publications

  1. ncbi Cost considerations in the treatment of colorectal cancer
    Frank G A Jansman
    Groningen University Institute for Drug Exploration, Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:537-62. 2007
  2. ncbi Total body topical 5-fluorouracil for extensive non-melanoma skin cancer
    Serge van Ruth
    Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Pharm World Sci 28:159-62. 2006
  3. ncbi Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer
    F G Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 23:255-78. 2000
  4. ncbi Fatal anaphylactoid reaction following ioversol administration
    Frank Ga Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Pharm World Sci 29:584-6. 2007
  5. ncbi Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Clin Ther 27:327-35. 2005
  6. ncbi Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Clin Ther 26:579-89. 2004
  7. ncbi Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Groot Wezenland 20, P O Box 10500, 8000 GM Zwolle, The Netherlands
    Anticancer Res 22:3449-55. 2002
  8. ncbi Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer
    F G Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 24:353-67. 2001
  9. ncbi Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer
    Yuhan Kho
    Department of Clinical Pharmacy, Canisius Wilhelmina Ziekenhuis Nijmegen, The Netherlands
    Ther Drug Monit 28:206-11. 2006
  10. ncbi Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature
    Indra Chedoe
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 30:503-13. 2007

Collaborators

Detail Information

Publications13

  1. ncbi Cost considerations in the treatment of colorectal cancer
    Frank G A Jansman
    Groningen University Institute for Drug Exploration, Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:537-62. 2007
    ....
  2. ncbi Total body topical 5-fluorouracil for extensive non-melanoma skin cancer
    Serge van Ruth
    Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Pharm World Sci 28:159-62. 2006
    ..No detectable serum level of 5-fluorouracil could be determined. Pain and secondary infections were important side effects in our patients. However, in patients with extensive NMSC this treatment may be considered...
  3. ncbi Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer
    F G Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 23:255-78. 2000
    ....
  4. ncbi Fatal anaphylactoid reaction following ioversol administration
    Frank Ga Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Pharm World Sci 29:584-6. 2007
    ..Especially patients with risk factors for side-effects should be monitored carefully...
  5. ncbi Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Clin Ther 27:327-35. 2005
    ..Pharmacokinetic and pharmacodynamic drug interactions with cytotoxic drugs may significantly influence the efficacy and toxicity of chemotherapy...
  6. ncbi Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Clin Ther 26:579-89. 2004
    ..In 2 Phase III trials, capecitabine was at least as effective as 5-fluorouracil plus leucovorin and had a more favorable toxicity profile...
  7. ncbi Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Groot Wezenland 20, P O Box 10500, 8000 GM Zwolle, The Netherlands
    Anticancer Res 22:3449-55. 2002
    ..Dose adaptation based on pharmacokinetic parameters has been shown to decrease toxicity of some 5-fluorouracil(5-FU)-based continuous infusion regimens...
  8. ncbi Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer
    F G Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 24:353-67. 2001
    ..For optimal management of adverse effects, patients should be considered individually, while patients, nurses and physicians should cooperate to identify and treat adverse effects in an early stage of their development...
  9. ncbi Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer
    Yuhan Kho
    Department of Clinical Pharmacy, Canisius Wilhelmina Ziekenhuis Nijmegen, The Netherlands
    Ther Drug Monit 28:206-11. 2006
    ..This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing. The results of this study suggest that fractionated urine samples can replace 24-hour urine collection...
  10. ncbi Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature
    Indra Chedoe
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Drug Saf 30:503-13. 2007
    ..Some of these research efforts need to be directed to the establishment of clear definitions of medication errors and agreement on the methods that should be used to measure medication error rates and their potential clinical impact...
  11. ncbi Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer
    Frank G A Jansman
    Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Am J Health Syst Pharm 62:1788-93. 2005
  12. ncbi Evaluation of pharmacist clinical interventions in a Dutch hospital setting
    Liesbeth Bosma
    Hospital Pharmacy, Isala Klinieken, Zwolle, The Netherlands
    Pharm World Sci 30:31-8. 2008
    ..Assessing the relevance of a clinically active pharmacist method compared to the traditional working method...
  13. ncbi Case report medication error: oral antibiotics and simethicone accidentally injected intravenously
    Rolf C Mahne
    Intensive Care Med 29:1398. 2003